Primary Nasopharyngeal Melanoma without invasive and Metastasis: A Rare Case Reports and Literature Reviews.

Ear Nose Throat JMar 4, 2024 (epub)

Jian-Jun Wang, Yao-Dong Huan, Hua Liu

✦ AI-curated · Sources linked

Case in brief

A 59-year-old man presented with persistent nasal congestion and a suspected malignant nasopharyngeal neoplasm. Imaging showed no tissue invasion or lymph-node metastases. The resected lesion was diagnosed as malignant nasopharyngeal melanoma, with immunohistochemistry positive for Melan-A, HMB45, and S100. He underwent complete surgical resection followed by adjuvant radiotherapy. At 2 years of follow-up, there was no recurrence or metastasis, and the reported prognosis was good.

What made this case unusual

Despite the generally poor prognosis described for nasopharyngeal melanoma, this case had no imaging evidence of invasion or nodal metastasis and remained free of recurrence and metastasis at 2 years.

Diagnostic / clinical pearl

In a suspected nasopharyngeal malignancy, immunohistochemical positivity for Melan-A, HMB45, and S100 supported the diagnosis of mucosal melanoma in this case.

Source

Published in Ear Nose Throat J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.